



22 September 2025

Medicine Supply Alert Notice

Admelog® (insulin lispro) 100units/ml solution for injection 3ml cartridges

Admelog® (insulin lispro) 100units/ml solution for injection 3ml pre-filled pens

Admelog® (insulin lispro) 100units/ml solution for injection 10ml vials

Priority: Level 2*
Valid until: June 2026

Issue

1. Admelog® (insulin lispro) 100 units/ml solution for injection cartridges, pre-filled pens and vials are being discontinued with supplies anticipated to be exhausted by mid-March 2026, late March 2026 and mid-June 2026, respectively.
2. Humalog® (insulin lispro) 100units/ml solution for injection cartridges, KwikPens® and vials remain available and can support increased demand.

Advice and Actions

3. Clinicians should not initiate new people on Admelog®, which is a biosimilar insulin product.
4. Clinicians should review existing patients and consider switching to the originator insulin product, Humalog® 100units/ml solution for injection, which can fully support the increased demand.
5. When switching to a Humalog® product prescribers should:
 - ensure people are informed of the reason for the switch, establish whether additional support is required with administration, and reassure them that they are receiving the same type of insulin, but they may initially need to check blood glucose levels more closely and have their dose adjusted if required;
 - provide people with training on the use of their new insulin preparation if required (see Additional information), including signposting to training resources, and
 - where a person has been prescribed Humalog® cartridges, prescribe a HumaPen® SAVVIO® reusable pen and BD pen needles.
6. If the above options are not considered appropriate, advice should be sought from the diabetes team on use of other insulin products.

Additional Information

Clinical Information

*<https://www.nss.nhs.scot/media/1842/medicine-supply-alert-notice-definitions-of-classifications-21-october-2019.pdf>

7. Admelog® (insulin lispro) is a biosimilar of the rapid-acting insulin Humalog®. A switch to Humalog® on a dose for dose basis can be considered in patients with stable/good glucose control who are not experiencing hypoglycaemic episodes, with close monitoring of blood glucose after the switch, and dose titrated if necessary. Dosing of Humalog® should be individualised for less stable patients.

Pen devices

- Admelog® pre-filled pens dial up insulin in 1-unit increments allowing the delivery of 1-80 units in a single injection
- Admelog® 100 units/ml in cartridges are used with the following pens: JuniorSTAR® which delivers 1-30 units in 0.5-unit dose increments, Tactipen® which delivers 1-60 units in 1-unit dose increments, and AllStar® and AllStar® PRO which all deliver 1-80 units of insulin lispro in 1-unit dose increments
- Humalog® KwikPens® are pre-filled disposable pens that dial up insulin in 1-unit increments allowing the delivery of 1-60 units in a single injection
- Humalog® 3ml cartridges are compatible with the HumaPen® SAVVIO® reusable pen which dials up insulin in 1-unit increments allowing the delivery of 1-60 units in a single injection
- For doses of greater than 60 units delivered from Humalog® KwikPens® or cartridges (via a HumaPen® SAVVIO® reusable pen), multiple injections will be needed
- The HumaPen® SAVVIO® reusable pen and Humalog® KwikPens® are suitable for use with BD pen needles

Specialist Pharmacy Service (SPS) website

8. The UK Department of Health and Social Care (DHSC) in conjunction with SPS have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.

9. We encourage prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

10. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).